The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
This treatment uses vacuum to remove excess fluid and cellular waste that usually prolongs the inflammatory phase of wound healing. Despite a straightforward mechanism of action, the results of negative pressure wound therapy studies have been inconsistent. Research needs to be carried out to optimize the parameters of pressure intensity, treatment intervals, and exact timing to start negative pressure therapy in the course of chronic wound healing. There is low-certainty evidence that negative pressure wound therapy would improve wound healing in diabetic foot ulcers.
== Adverse effects == Cetacaine has been known to cause adverse effects in the patients it has been administered to. These include hypersensitivity in the form of anaphylaxis, dermatitis, erythema, pruritus which can lead to oozing and vesiculation. There have also been accounts of rashes, edema, urticarial and other allergic symptoms as well as methemoglobinemia. Other adverse effects can include: tremors, twitching, dizziness, confusion, hypo-tension, vomiting, euphoria, and blurred or double vision.
== Symptoms and signs == NAION typically presents suddenly upon awakening. The affected person notes seeing poorly in one eye. Vision in that eye is obscured by a dark shadow, often involving just the upper or lower half of vision, usually the area closer to the nose. There is no pain. Within approximately six months following the infarct, visual acuity improves by three or more lines of vision on the Snellen Chart (the chart with smaller letters on each lower line) in 42.7% of patients, while in 12.4% of patients, vision worsens by three lines. Opposite eye involvement occurs in approximately 15% to 20% of patients with NAION within 5 years. It is not always devastating as visual acuity may remain only moderately impaired. Furthermore, most cases of NAION involve the loss of a hemifield (either the upper or lower half of the visual field, but not both). A few cases of NAION involve near-total loss of vision.
Communicates with sensory neurons. Mesencephalon Also known as the midbrain, this region of the brainstem is involved in motor control, vision, hearing, and alertness. Metabotropic receptor A type of neurotransmitter receptor that activates a second messenger system via G-proteins, resulting in slower but longer-lasting cellular effects. Microelectrode A very fine electrode used to record the electrical activity of individual neurons. Microglia The resident immune cells of the central nervous system, responsible for clearing debris, responding to injury, and regulating inflammation. Middle ear The air-filled space containing the auditory ossicles (malleus, incus, stapes) that transmit sound from the outer ear to the inner ear. Midbrain A portion of the brainstem that includes structures such as the tectum and tegmentum. It plays roles in vision, hearing, motor control, and arousal. Mismatch negativity (MMN) An event-related potential detected via EEG that reflects automatic brain response to deviations in auditory stimuli. Used in studies of perception and schizophrenia. Mitochondria Organelles responsible for energy production in cells. In neurons, they play critical roles in metabolism, calcium regulation, and apoptosis. Molecular layer The outermost layer of the cerebellar cortex and cerebral cortex (in some regions), containing relatively few neurons and mostly dendrites, axons, and synapses. Monoamine oxidase (MAO) An enzyme that breaks down monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine. Targeted by some antidepressants.
Skeletal advancement to physically increase the pharyngeal airspace is often an option for craniofacial patients with upper airway obstruction and small lower jaws (mandibles). These syndromes include Treacher Collins syndrome and Pierre Robin sequence. Mandibular advancement surgery is one of the modifications needed to improve the airway; others may include reduction of the tongue, tonsillectomy, or modified uvulopalatoplasty.
Sources: en.wikipedia.org
== Origins of microscopic pathology == Rudolf Virchow (1821–1902) is generally recognized to be the father of microscopic pathology. While the compound microscope had been invented approximately 150 years prior, Virchow was one of the first prominent physicians to emphasize the study of manifestations of disease which were visible only at the cellular level. A student of Virchow's, Julius Cohnheim (1839–1884) combined histology techniques with experimental manipulations to study inflammation, making him one of the earliest experimental pathologists. Cohnheim also pioneered the use of the frozen section procedure; a version of this technique is widely employed by modern pathologists to render diagnoses and provide other clinical information intraoperatively.
The Pantheon of Skeptics was created by CSI to remember the legacy of deceased fellows of CSI and their contributions to the cause of scientific scepticism. A sculpted bust of Francis Crick by John Sherrill Houser, which incorporates a single "Golden" Helix, was cast in bronze in the artist's studio in New Mexico, US. The bronze was first displayed at the Francis Crick Memorial Conference (on Consciousness) at Churchill College, Cambridge on 7 July 2012; it was bought by Mill Hill School in May 2013, and displayed at the inaugural Crick Dinner on 8 June 2013, and was again at their Crick Centenary Dinner in 2016. The Benjamin Franklin Medal for Distinguished Achievement in the Sciences of the American Philosophical Society (2001), together with Watson. Crick featured in the BBC Radio 4 series The New Elizabethans to mark the Diamond Jubilee of Elizabeth II in 2012. A panel of seven academics, journalists and historians named Crick among a group of 60 people in the UK "whose actions during the reign of Elizabeth II have had a significant impact on lives in these islands and given the age its character".
Hence, in rats, vosilasarm is a potent full agonist of the levator ani muscle but a partial agonist and antagonist of the prostate and seminal vesicles, and is strongly selective for stimulating the levator ani muscle over the prostate gland. In young male cynomolgus monkeys, vosilasarm, at oral doses of 0.01 mg/kg/day, 0.1 mg/kg/day, and 1 mg/kg/day for 28 days, dose-dependently stimulated body weight (+10% at ≥0.1 mg/kg/day) and numerically increased lean body mass. The lack of statistical significance was likely due to the small sample sizes per dosing group (n=3 each). No data on vosilasarm and lean body mass in humans have been published as of 2022.
=== Film adaptation === In February 2013, Valve president Gabe Newell and film director J. J. Abrams announced that they were to collaborate on a film adaptation of the Portal series. In 2016, Abrams stated that he still has plans to direct these films in the future, with both films in the writing stage. Abrams confirmed in May 2021 that the film adaptation was still in the works as they were still working on a script for the film from Warner Bros. Pictures. In 2026, Kane Parsons also expressed interest in directing a Portal film.
Sources: en.wikipedia.org
==== History ==== It was founded in March 1979 as part of the People's Liberation Army Basic Engineering Corps. It was under the joint dual command of the Basic Engineering Corps and the Ministry of Metallurgical Industry. It consisted of 7 regiment level battalions and 12 geological teams. The Gold Corps was handed to the PAP in January 1985. After 1985, it went under the dual control of the Ministry of Metallurgical Industry and Ministry of Public Security. Its role in this time was to do geological surveys for gold mining. After February 1999, it went under the dual control of the People's Armed Police and the State Economic and Trade Commission. Its official duties were: finding gold deposits, providing security and law enforcement to gold mines, mining gold and preventing conflict near gold mines. By 2011, the gold corps had mined 1800 tonnes of gold. The same year in December, its official role switched again to geological surveying and metal analysis along with disaster relief to geological related incidents and law enforcement. In 2016, its role was switched yet again to focus primarily on military geology related work in the Deepening National Defense and Military Reform. In 2018, the Gold Corps was disbanded and its personnel were handed to the Ministry of Natural Resources, the China Geological Survey and the China National Gold Group Corporation.
=== Academic Health Center and UC Health (1980s-Present) === The medical school and health colleges had been referred to as the "University of Cincinnati Medical Center" from the early 1980s until 2005. In 2000 a fourth College, the College of Allied Health Sciences joined the University of Cincinnati Medical Center. In 2005, the name was changed from the University of Cincinnati Medical Center to the University of Cincinnati Academic Health Center. In 2010, the Academic Health Center (AHC) became part of the newly formed UC Health organization. UC Health was formed after the dissolution of the Health Alliance of Greater Cincinnati, which had operated the University of Cincinnati Medical Center from 1994 to 2010 and also operated West Chester Hospital starting in 2009. The 2010 dissolution of the alliance left the university with 100% ownership so the alliance was renamed to UC Health and placed under a parent company named UC Healthcare System.
It is clear that using oxygen to completely oxidize glucose provides an organism with far more energy than any oxygen-independent metabolic feature, and this is thought to be the reason why complex life appeared only after Earth's atmosphere accumulated large amounts of oxygen.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.